Literature DB >> 19233678

Mitral valve surgery plus concomitant atrial fibrillation ablation is superior to mitral valve surgery alone with an intensive rhythm control strategy.

Ulrich O von Oppell1, Navroz Masani, Peter O'Callaghan, Richard Wheeler, Georgios Dimitrakakis, Sandra Schiffelers.   

Abstract

OBJECTIVE: Prospective randomised study comparing patients with atrial fibrillation (AF) of more than 6 months duration after mitral valve surgery plus biatrial modified radiofrequency Maze procedure using Medtronic Cardioblate System (Cardioblate group, n=24) vs mitral valve surgery plus intensive rhythm control strategy (control group, n=25).
METHODS: Patients were blinded to randomisation. Preoperatively, at discharge, and at 3-month and 1-year follow-up, echocardiography, quality of life assessments and ECGs were done. In both groups, sinus rhythm (SR) restoration was attempted by intra- and postoperative DC cardioversion and class III antiarrhythmic medication. All patients received warfarin. Amiodarone and warfarin was considered for discontinuation after 3 months in SR, 24-h Holter or event monitor excluding AF.
RESULTS: Both groups underwent mitral valve replacement or repair (Cardioblate vs control: 16:8 vs 10:15), had similar gender (male: 33% vs 56%), age (66+/-8 years vs 68+/-9 years), additional aortic valve replacement (7 vs 6 patients), tricuspid annuloplasty (13 vs 13 patients), and CABG (10 vs 16 patients). There was 0% operative mortality, 0% postoperative cerebrovascular accidents, but 2 late deaths in the control group. At discharge, 3- and 12-month follow-up, more patients in the Cardioblate group returned to normal SR compared to control (29%, 57% and 75% vs 20%, 43% and 39%; p=0.030). Return of functional atrial contraction in patients in SR at 1 year was comparable between groups (63% vs 89%, NS), and more likely in non-rheumatic pathology and preoperative AF of shorter duration. The effectiveness of atrial contraction was 36+/-14% vs 43+/-18% of transmitral flow and there was no difference between groups. Amiodarone treatment decreased more in Cardioblate group over time (92%, 55% and 29% vs 52%, 52% and 21%; p=0.003), whereas warfarin decrease was comparable (100%, 100% and 71% vs 100%, 95% and 82%; NS).
CONCLUSIONS: Radiofrequency Maze ablation additional to mitral valve surgery resulted in a higher SR conversion rate (75%), despite control group treatment with intensive rhythm control strategy having a higher SR conversion rate (39%) compared to literature (approximately 25%). Maze ablation resulted in normalisation of atrial function in 63% of patients converted to SR.

Entities:  

Mesh:

Year:  2009        PMID: 19233678     DOI: 10.1016/j.ejcts.2008.12.042

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  26 in total

1.  Atrial function after left atrial epicardial cryoablation for atrial fibrillation in patients undergoing mitral valve surgery.

Authors:  Birgitta Johansson; Odd Bech-Hanssen; Eva Berglin; Per Blomström; Anders Holmgren; Steen M Jensen; Göran Källner; Leif Nilsson; Stefan Thelin; Thomas Karlsson; Nils Edvardsson; Carina Blomström-Lundqvist
Journal:  J Interv Card Electrophysiol       Date:  2011-09-21       Impact factor: 1.900

2.  eComment. atrial fibrillation ablation - are we approaching an equivalent standard of cure?

Authors:  Ulrich O Von Oppell; George Dimitrakakis
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-04

3.  A review of current surgical treatment of patients with atrial fibrillation.

Authors:  Zachary J Edgerton; James R Edgerton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2012-07

4.  Incremental risk of the Cox-maze IV procedure for patients with atrial fibrillation undergoing mitral valve surgery.

Authors:  Lindsey L Saint; Ralph J Damiano; Phillip S Cuculich; Tracey J Guthrie; Marc R Moon; Nabil A Munfakh; Hersh S Maniar
Journal:  J Thorac Cardiovasc Surg       Date:  2013-08-30       Impact factor: 5.209

Review 5.  How effective is bipolar radiofrequency ablation for atrial fibrillation during concomitant cardiac surgery?

Authors:  Sumoyee Basu; Myura Nagendran; Mahiben Maruthappu
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-07-19

Review 6.  Atrial fibrillation: review of current treatment strategies.

Authors:  Joshua Xu; Jessica G Y Luc; Kevin Phan
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

7.  Surgical ablation of atrial fibrillation during mitral-valve surgery.

Authors:  A Marc Gillinov; Annetine C Gelijns; Michael K Parides; Joseph J DeRose; Alan J Moskowitz; Pierre Voisine; Gorav Ailawadi; Denis Bouchard; Peter K Smith; Michael J Mack; Michael A Acker; John C Mullen; Eric A Rose; Helena L Chang; John D Puskas; Jean-Philippe Couderc; Timothy J Gardner; Robin Varghese; Keith A Horvath; Steven F Bolling; Robert E Michler; Nancy L Geller; Deborah D Ascheim; Marissa A Miller; Emilia Bagiella; Ellen G Moquete; Paula Williams; Wendy C Taddei-Peters; Patrick T O'Gara; Eugene H Blackstone; Michael Argenziano
Journal:  N Engl J Med       Date:  2015-03-16       Impact factor: 91.245

8.  Impact of epicardial ablation of concomitant atrial fibrillation on atrial natriuretic peptide levels and atrial function in 6 months follow-up: does preoperative ANP level predict outcome of ablation?

Authors:  Marek Pizon; Norbert Friedel; Monika Pizon; Miriam Freundt; Michael Weyand; Richard Feyrer
Journal:  J Cardiothorac Surg       Date:  2013-11-28       Impact factor: 1.637

9.  Right minithoracotomy versus conventional median sternotomy for patients undergoing mitral valve surgery and Cox-maze IV ablation with entirely bipolar radiofrequency clamp.

Authors:  Zhaolei Jiang; Min Tang; Nan Ma; Hao Liu; Fangbao Ding; Chunrong Bao; Ju Mei
Journal:  Heart Vessels       Date:  2018-02-02       Impact factor: 2.037

Review 10.  Novel approaches for the surgical treatment of atrial fibrillation: time for a guideline revision?

Authors:  Carlo Nicola De Cecco; Vitaliano Buffa; Vincenzo David; Stefano Fedeli
Journal:  Vasc Health Risk Manag       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.